<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239170</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-GEMOX-IIT-HL</org_study_id>
    <nct_id>NCT04239170</nct_id>
  </id_info>
  <brief_title>Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>An Open-lable, Single Arm, Phase 2 Study of Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Will Receive ASCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1
      inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory
      hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano
      criteria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>From first patient first visit to 3 month after last patient first visit</time_frame>
    <description>Based on Lugano 2014 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From first patient first visit to 3 month after last patient first visit</time_frame>
    <description>Rate of subjects achieved complete response plus partial response in all evaluable subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab(SHR-1210) Combined With GEMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab(SHR-1210)</intervention_name>
    <description>Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin</description>
    <arm_group_label>Camrelizumab(SHR-1210) Combined With GEMOX</arm_group_label>
    <other_name>GEMOX(Gemcitabine, Oxaliplatin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed classic Hodgkin's lymphoma ;

          2. Relapsed or refractory cHL and meet any of the following criterions:a)did not achieve
             remission or progression and will receive autologous hematopoietic stem cell
             transplantation.b)receive no more than 3 lines of systemic chemotherapy.

          3. Subjects enrolled have measurable lesion(s) according to Lugano 2014 criteria

          4. ECOG performance status of 0 or 1;

          5. Life expectancy ≥ 12 weeks.;

          6. Adequate laboratory parameters during the screening period as evidenced by the
             following:

               1. Hemoglobin ≥ 90 g/L;

               2. Absolute neutrophil count ≥ 1.5 × 109/L ;

               3. Platelets ≥ 100 × 109/L;

               4. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN),

               5. ALT and AST ≤ 2.5×ULN

               6. Serum Creatinine ≤1.25×ULN or Creatinine clearance≥60 mL/min;

               7. Coagulation function index：INR ≤1.5×ULN，APTT≤1.5×ULN

          7. Women of childbearing potential（WOCBP）with pregnancy test negative within 7 days
             before entering the group and consent to employ a highly effective method of birth
             control/contraception to prevent pregnancy for at least 1 year after receiving the
             last dose of study treatment; Male subjects with WOCBP partner should receive Surgical
             sterilization or consent to employ a highly effective method of birth
             control/contraception to prevent pregnancy for at least 1 year after receiving the
             last dose of study treatment.

          8. Able to understand and sign an informed consent form (ICF).

        Exclusion Criteria:

          1. Known nodular lymphoma predominant Hodgkin lymphoma

          2. History and complication as follows,

               1. Active, known or suspected autoimmune disease. Subjects who were in a stable
                  state without systemic immunosuppressive therapy were admitted

               2. Concurrent medical condition requiring the use of immunosuppressive medications,
                  or immunosuppressive doses of systemic corticosteroids &gt; 10 mg/day topical
                  prednisone or equivalent are prohibited within 2 weeks before entering the group

               3. Received anti-tumor vaccines or other anti-tumor therapy with immune stimulation
                  within 3 months before the first dose of trial drugs.

               4. Prior exposure to any PD-1/PD-L1/PD -L 2 or CTLA -4 antibody . Or prior exposure
                  to GEMOX but PD.

               5. Participating in other clinical studies or less than 4 weeks before the end of a
                  clinical trial.

               6. Known and highly Suspicion of interstitial pneumonia.

               7. Other active malignancies that required treating. (subjects with skin basal cell
                  carcinoma, superficial bladder cancer, skin squamous cell carcinoma or cervical
                  carcinoma who had no disease recurrence within 5 years after the start of
                  treatment were excluded).

               8. Received chemotherapy, radiotherapy,immunotherapy, including topical therapy
                  within 4 weeks. Previous anti-tumor therapy related adverse reactions (except
                  hair loss) did not recover to CTCAE ≤1.

               9. Prior allo-HSCT.

              10. Impact of major surgery or severe trauma had been eliminated for less than 28
                  days

              11. Active pulmonary tuberculosis.

              12. Severe acute or chronic infection requiring systemic therapy.

              13. Suffering from high blood pressure, and cannot be well controlled by
                  antihypertensive drugs (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90
                  mmHg)

              14. Suffering from heart failure (New York Heart Association standard III or IV).
                  Uncontrolled coronary artery disease and arrhythmia although given appropriate
                  medical treatment. History of myocardial infarction within 6 months.

              15. Three months before randomization, there were significant bleeding symptoms or
                  definite bleeding tendency, such as gastrointestinal bleeding, bleeding gastric
                  ulcer, stool occult blood test is ++ at baseline and above, or vasculitis

          3. Laboratory test

               1. Known HIV positive or known AIDS.

               2. Untreated active hepatitis: Hepatitis B(HBsAg positive and HBV DNA≥500IU/mL), and
                  hepatitis C(HCV RNA positive, abnormal liver function) ,Hepatitis B and hepatitis
                  C infection in common.

          4. Other factors that may lead to the study termination, such as severe disease or
             abnormal laboratory tests or family or social factors affecting subjects safety or
             test data and sample collection.

          5. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuqin Song, MD</last_name>
    <phone>(+8610)88196118</phone>
    <email>SongYQ_VIP@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu, MD</last_name>
      <phone>(+8610)88196596</phone>
      <email>Zj@bjcancer.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Party secretary of Cancer Hospital of Peking University, Director of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

